Trial Profile
A 12-month, Phase IV, Open-label, Randomized, Active Controlled, 2-arm, Multicenter Study Assessing the Efficacy and Safety of Intravitreal Ranibizumab Combined With Grid&Direct Short Pulse Laser Photocoagulation Versus a PRN Ranibizumab Monotherapy in Japanese Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 25 Jan 2019 Status changed from active, no longer recruiting to completed.
- 14 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2018 Planned End Date changed from 15 Nov 2018 to 27 Dec 2018.